Invivyd Inc (IVVD)
Invivyd, Inc. is a biotechnology company focused on the research, development, commercialization, and sale of antibody therapies aimed at preventing and treating viral infectious diseases in the United States. Its lead product, Pemivibart, is a half-life extended investigational monoclonal antibody for pre-exposure prophylaxis against COVID-19 in adults and adolescents, marketed through injection under the PEMGARDA brand. The company is also advancing VYD2311, a monoclonal antibody in Phase III development for the prevention and treatment of SARS-CoV-2, and VBY329, a pre-clinical monoclonal antibody candidate for respiratory syncytial virus and measles in neonates, infants, and children. Invivyd also maintains a collaboration with Adimab, LLC for antibody discovery and optimization. Formerly known as Adagio Therapeutics, Inc., the company adopted the Invivyd name in September 2022 and is headquartered in New Haven, Connecticut.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-IVVD
|
$1.17
|
21.9% Upside
|
Undervalued
|
$10
|
937.3% Upside
|
Bargain
|
Good
|
0.0%
|
November 5, 2026
|
1.7x
|
5.2x
|
284.1 M
|
149 M
|
2.7%
|
70.5%
|
-2.5
|
102.2%
|
